How Will Aimmune Therapeutics (AIMT) Stock React To New Rating Coverage byPiper Jaffray?

May 18, 2018 - By Lynda A. Deweese

Aimmune Therapeutics, Inc. (NASDAQ:AIMT) Logo

Why Has Piper Jaffray Given Aimmune Therapeutics (AIMT) a $60.0000 Price Target

In an analyst note made public on Friday, 18 May, expert analysts at Piper Jaffray has started coverage for Aimmune Therapeutics (AIMT) shares. The firm has decided to set a “Buy” rating along with a $60.0000, adding 99.93 % to the target.

Aimmune Therapeutics, Inc. (NASDAQ:AIMT) Ratings Coverage

Among 8 analysts covering Aimmune Therapeutics (AIMT), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Aimmune Therapeutics has $80.0 highest and $30.0 lowest target. $59.25’s average target is 97.43% above currents $30.01 stock price. Aimmune Therapeutics had 22 analyst reports since November 20, 2017 according to SRatingsIntel. The stock of Aimmune Therapeutics, Inc. (NASDAQ:AIMT) earned “Buy” rating by Roth Capital on Wednesday, January 31. The company was maintained on Friday, February 23 by Wedbush. Cantor Fitzgerald maintained Aimmune Therapeutics, Inc. (NASDAQ:AIMT) rating on Sunday, March 25. Cantor Fitzgerald has “Buy” rating and $6400 target. The firm has “Buy” rating by Piper Jaffray given on Tuesday, December 5. The firm has “Buy” rating given on Tuesday, February 27 by Credit Suisse. As per Thursday, April 5, the company rating was maintained by Piper Jaffray. The stock of Aimmune Therapeutics, Inc. (NASDAQ:AIMT) earned “Buy” rating by Cantor Fitzgerald on Thursday, March 1. Wedbush maintained it with “Buy” rating and $72.0 target in Wednesday, March 14 report. The firm has “Buy” rating by Roth Capital given on Monday, March 5. As per Tuesday, February 20, the company rating was maintained by Cantor Fitzgerald.

The stock increased 0.17% or $0.05 during the last trading session, reaching $30.01. About 288,238 shares traded. Aimmune Therapeutics, Inc. (AIMT) has risen 29.28% since May 18, 2017 and is uptrending. It has outperformed by 17.73% the S&P500.

Analysts await Aimmune Therapeutics, Inc. (NASDAQ:AIMT) to report earnings on August, 14. They expect $-0.68 EPS, down 4.62 % or $0.03 from last year’s $-0.65 per share. After $-0.92 actual EPS reported by Aimmune Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -26.09 % EPS growth.

Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies in the United States and Europe. The company has market cap of $1.74 billion. The Company’s lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy. It currently has negative earnings. Aimmune Therapeutics, Inc. has strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics.

More notable recent Aimmune Therapeutics, Inc. (NASDAQ:AIMT) news were published by: 247Wallst.com which released: “Top Analyst Upgrades and Downgrades: Aimmune, Anadarko, Carrizo, Mastercard, PayPal, Spotify, Visa and More” on May 18, 2018, also Seekingalpha.com with their article: “Backing Blackstone For A Decade – Cramer’s Lightning Round (4/23/18)” published on April 24, 2018, Businesswire.com published: “Aimmune Therapeutics to Present Data on Peanut Allergy at the European Academy of Allergy and Clinical …” on May 15, 2018. More interesting news about Aimmune Therapeutics, Inc. (NASDAQ:AIMT) were released by: Streetinsider.com and their article: “Piper Jaffray Assumes Aimmune Therapeutics (AIMT) at Overweight” published on May 18, 2018 as well as Seekingalpha.com‘s news article titled: “Premarket analyst action – healthcare” with publication date: May 18, 2018.

Aimmune Therapeutics, Inc. (NASDAQ:AIMT) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.